Novo Nordisk has developed a new version of the insulin analogue, called Fiasp, which added another DKK 1.6 billion to the fast-acting insulin pot last year and has patent protection to 2030.

Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...

Africa's diabetes market is set to grow 7.2% annually, reaching $2.73 billion by 2025. Key trends include expanding CGM access, supporting local prod ...

The AI in Life Science Market is anticipated to experience a remarkable compound annual growth rate (CAGR) of around 25% in ...

Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its ...

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

Inhaled insulin is effective for controlling blood sugar levels in children with diabetes, providing them with a ...

Novo Nordisk A/S (NYSE:NVO) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 23, Novo Nordisk A ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...